Know Cancer

or
forgot password

Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin


Phase 1/Phase 2
16 Years
80 Years
Not Enrolling
Both
Head and Neck Cancer

Thank you

Trial Information

Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin


OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicities of high
dose yttrium Y 90 monoclonal antibody MN-14 with or without doxorubicin plus peripheral
blood stem cell rescue in patients with medullary thyroid cancer. II. Correlate organ and
tumor dosimetry with toxicity and antitumor responses in these patients. III. Assess
response and duration of response in these patients after this treatment.

OUTLINE: This is a dose escalation study of yttrrium Y 90 monoclonal antibody MN-14
(90Y-MN-14). Patients are stratified by prior doxorubicin (yes vs no). Patients receive
filgrastim (G-CSF) subcutaneously (SQ) on days -11 to -7 and undergo leukapheresis on days
-8 to -6. If an adequate number of CD34+ cells are not harvested, bone marrow is also
collected. Patients receive pretherapy targeting consisting of indium In 111 monoclonal
antibody MN-14 (In111-MN-14) on day 0. At least 1 confirmed tumor site must be targeted.
Patients receive 90Y-MN-14 IV over 30-45 minutes on day 7. Some patients also receive
doxorubicin IV on day 8. PBSC or bone marrow is reinfused on approximately day 7-14.
Patients also receive G-CSF SQ or IV until blood counts recover. Cohorts of 3-6 patients
receive escalating radiological doses of 90Y-MN-14 until the maximum tolerated dose (MTD) is
determined. The MTD is defined as either the dose at which no more than 1 of 6 patients
experiences dose limiting toxicity or the threshold radiation doses to lungs, kidneys, and
liver. Patients are followed weekly for the first month, monthly for 3 months, then every 6
months for up to 5 years.

PROJECTED ACCRUAL: Approximately 30 patients will be accrued for each stratum of this study
within 3 years.

Inclusion Criteria


DISEASE CHARACTERISTICS: Histologically or cytologically proven medullary thyroid
carcinoma Unresectable local-regional disease OR Distant metastases Autologous peripheral
blood stem cells (PBSC) or bone marrow available Diffuse bone/marrow involvement allowed
if: Autologous bone marrow or PBSC with no greater than 5% tumor involvement available
Radiation dose to marrow no greater than 3000 cGy until 6 patients have been treated
safely at that dose level At least 1 site confirmed by CT targeted by pretherapy indium In
111 monoclonal antibody MN-14 imaging

PATIENT CHARACTERISTICS: Age: 16 to 80 Performance status: Karnofsky 60-100% ECOG 0-2 Life
expectancy: At least 3 months Hematopoietic: WBC at least 3000/mm3 Granulocyte count at
least 1500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2
mg/dL Renal: Creatinine less than 1.5 times upper limit of normal Cardiovascular: Ejection
fraction at least 50% Other: No severe anorexia, nausea, or vomiting No concurrent
significant medical complications that would preclude compliance Not pregnant Fertile
patients must use effective contraception during and for 3 months after study

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since biologic therapy
Chemotherapy: At least 4 weeks since prior chemotherapy and recovered No greater than 240
mg/m2 doxorubicin total for combination therapy with doxorubicin but no greater than 550
mg/m2 doxorubicin if radioimmunotherapy alone No prior failure on doxorubicin therapy for
combination therapy but not radioimmunotherapy alone Endocrine therapy: Prior synthroid
(T4) allowed Radiotherapy: See Disease Characteristics At least 4 weeks since prior
radiotherapy to index lesion and recovered No prior radiotherapy to greater than 35% of
red marrow Surgery: At least 4 weeks since prior major surgery

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

Jack D. Burton, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Authority:

United States: Food and Drug Administration

Study ID:

CDR0000067172

NCT ID:

NCT00004048

Start Date:

September 1998

Completion Date:

May 2002

Related Keywords:

  • Head and Neck Cancer
  • thyroid gland medullary carcinoma
  • Thyroid Neoplasms
  • Head and Neck Neoplasms

Name

Location

St. Joseph's Hospital and Medical CenterPaterson, New Jersey  07503
Garden State Cancer CenterBelleville, New Jersey  07103